Dementia Australia has welcomed the recent approval of Lecanemab by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). This development marks a significant advance in the battle against Alzheimer’s disease, offering renewed optimism for those affected by this debilitating condition.
Lecanemab, produced by the pharmaceutical company Eisai, has been making waves across the globe. Already approved for use in the United States, Japan, China, South Korea, and Israel, it is now being considered by Australia’s Therapeutic Goods Administration. The drug targets amyloid plaques in the brain, which are known to play a critical role in the progression of Alzheimer’s disease. By removing these plaques, Lecanemab has shown the potential to slow down the decline in cognitive abilities and daily functioning in those in the early stages of Alzheimer’s.
Professor Christopher Rowe, the director of the Australian Dementia Network (ADNeT), has praised the UK’s approval, highlighting its importance in the broader context of Alzheimer’s treatment. “This is not a cure,” he acknowledged, “but it is an exciting and historic first step towards reducing the enormous impact that Alzheimer’s has on individuals, families, carers, and the healthcare system.”
Professor Rowe also pointed out that Lecanemab is just one of several promising treatments currently under development. Together, these advancements could herald a new era in the management of Alzheimer’s disease, offering hope to millions of people worldwide.
However, the path to widespread use in the UK is not entirely clear. Despite the MHRA’s approval, the National Institute for Health and Care Excellence (NICE) has released draft guidance advising against providing Lecanemab through the National Health Service (NHS). This decision could limit access to the drug, leaving many patients and their families in a difficult position as they navigate their treatment options.
Dementia Australia’s CEO, Professor Tanya Buchanan, expressed her anticipation for Lecanemab’s potential approval in Australia. “Although this treatment may not be suitable for everyone, it represents a significant step forward in the treatment of Alzheimer’s disease. We are hopeful that Australians will soon have the option to access Lecanemab, provided it is deemed clinically appropriate,” she said.
Professor Buchanan also emphasised the broader implications of this development. “This is an exciting time in the field. While Lecanemab is not a magic bullet, it represents the first step towards effective treatments for Alzheimer’s disease.”
As the medical community continues to search for more effective ways to combat Alzheimer’s, the approval of Lecanemab in the UK is a beacon of hope. For those living with the disease, as well as their loved ones, this new drug offers a glimmer of optimism in what has often been a bleak landscape. The world will be watching closely as more countries, including Australia, consider the approval of Lecanemab, and as further research into Alzheimer’s treatments progresses.
Support independent community journalism. Support The Indian Sun.
Follow The Indian Sun on X | Instagram | Facebook
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
